查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1722409

2025-2033年眼科藥物市場報告（按類型、藥品類別、適應症、劑型、配銷通路和地區）

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024年全球眼科藥物市場規模達472億美元。展望未來， IMARC Group預計到2033年市場規模將達到712億美元，2025-2033年期間的成長率（CAGR）為4.44%。市場受到以下因素的推動：被診斷患有眼疾的人數不斷增加、藥物輸送系統的重大技術進步、政府的有利舉措和資金、老年人口的增加以及糖尿病患者人數的增加。

眼科藥物市場分析：

主要市場促進因素：與眼睛相關的問題的日益增多、藥物配方的重大發展以及對技術和藥物研究領域的強勁投資是推動眼科藥物成長的一些主要市場促進因素。

主要市場趨勢：選擇聯合療法的個人數量不斷增加、行業參與者之間的策略夥伴關係不斷增加、以及對創造以前被認為無法治療的疾病的治療方法的日益重視是眼科藥物市場的一些趨勢。

地理趨勢：北美以其強大的醫療保健基礎設施和不斷增加的糖尿病相關眼部疾病診斷數量引領市場。該產業的第二大市場是歐洲，因為歐洲老齡人口不斷增加，且該地區的研發活動不斷增加。

競爭格局：AbbVie Inc.、Aerie Pharmaceuticals Inc.、Akorn Inc.、Alcon、Bausch Health Companies Inc.、Bayer AG、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Regeneron Pharmaceticals Inc.、Santenticals.

挑戰與機會：該市場的挑戰包括嚴格的監管環境，導致藥品核准延遲和開發的眼科藥物成本上升。此外，眼科藥物市場近期的機會包括因醫療保健管道不斷擴大而產生的新興市場潛力。

眼科藥物市場趨勢：

個人眼部疾病盛行率上升

全球範圍內日益增多的眼部問題大大增加了眼科藥物的需求。根據資料，白內障、青光眼、老年黃斑部病變（AMD）和糖尿病視網膜病變等疾病正在推動市場發展。根據世界衛生組織 (WHO) 的數據，每年至少有 22 億人患有近視或遠視障礙。報告也指出，至少有 10 億視力障礙病例本來是可以避免的，或尚未預防。患有眼部疾病的人數不斷增加，導致對抗青光眼藥物、抗 VEGF 藥物和抗發炎藥物等治療藥物的需求大幅增加。大量市場研究報告支持這種相關性，這些報告描述了有前景的先進治療方案並促進了眼科藥物市場最近的發展活動。

藥物輸送系統的重大技術進步

藥物輸送系統的創新可以歸功於新技術，這是創造積極的眼科藥物市場前景的主要因素。微乳劑、奈米技術或眼部插入物等新配方可提供更好的功效、安全性和患者依從性。例如，奈米級的藥物載體可以顯著提高藥物對目標眼組織的生物利用度，從而減少頻繁服藥的需要以及與藥物相關的任何副作用。因此，越來越多的公司正在投資這些技術以在市場上獲得競爭優勢。業內新型眼科給藥系統專利數量不斷增加。所有上述研發 (R&D) 投資均以受益於新藥物輸送技術的細分市場的市場成長預測為基礎。這意味著他們有能力顯著顛覆目前的眼科治療模式。

政府的優惠措施和資金

政府政策是創造積極眼科藥物市場前景的重要因素。世界各國政府已推出各種措施來改善醫療保健基礎設施，包括使有效的眼科護理更容易獲得。例如，許多國家提供機會資助開設和發展眼科保健中心、投資研究開發新藥以及傳播有關眼科疾病的訊息。在美國，國家眼科研究所為眼科領域的研究提供了大量資金。這推動了該領域的重大突破，為良好視力產業開闢了新的藥物和機會。此外，透過 FDA 的突破性療法認定等途徑加快藥物核准，提高了有遠見的眼科解決方案的市場准入。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球眼科藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 處方藥
  • 非處方藥

第7章：市場區隔：依藥品類別

  • 抗青光眼
  • 抗感染
  • 抗發炎
  • 抗過敏
  • 其他

第8章：市場區隔：依指標

  • 乾眼症
  • 青光眼
  • 感染/發炎/過敏
  • 視網膜疾病
  • 其他

第9章：市場區隔：按劑型

  • 液體眼科藥物劑型
  • 固體眼科藥物劑型
  • 半固體眼科藥物劑型
  • 多室藥物輸送系統
  • 其他

第10章：市場區隔：按配銷通路

  • 醫院藥房
  • 藥局
  • 網路藥局
  • 其他

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 12 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格分析

第 16 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: SR112025A5287

The global ophthalmic drugs market size reached USD 47.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 71.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

Breakup by Type:

  • Prescription Drugs
  • Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others

Anti-glaucoma holds the largest share in the industry

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Others

Retinal disorders represent the leading market segment

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

Hospital pharmacies dominates the market

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the ophthalmic drugs market?
  • 2.What is the future outlook of ophthalmic drugs market?
  • 3.What are the key factors driving the ophthalmic drugs market?
  • 4.Which region accounts for the largest ophthalmic drugs market share?
  • 5.Which are the leading companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2024
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2024
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players